Velcade 3.5mg Injection

About

Velcade 3.5mg Injection contains bortezomib, a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. The proteasome is a cellular complex responsible for degrading unwanted or damaged proteins, playing a critical role in cell cycle regulation, gene expression, and apoptosis. Bortezomib reversibly inhibits the 26S proteasome, leading to an accumulation of ubiquitinated proteins within the cell. This accumulation disrupts various cellular pathways, including NF-κB signaling, and ultimately induces apoptosis in cancer cells. Its targeted action makes it particularly effective against plasma cell dyscrasias and certain lymphomas. Velcade is typically administered intravenously or subcutaneously under strict medical supervision, often as part of a combination regimen.

Uses

• Treatment of multiple myeloma in adult patients.
• Management of mantle cell lymphoma in adult patients.
• Used in newly diagnosed multiple myeloma patients.
• Effective in relapsed or refractory multiple myeloma.

Directions For Use

Administer intravenously or subcutaneously by a healthcare professional. Dosage and schedule are determined by the physician based on the specific indication and patient factors.

Benefits

• Effective in treating multiple myeloma.
• Provides a treatment option for mantle cell lymphoma.
• Induces apoptosis in cancer cells by proteasome inhibition.
• Can be used as monotherapy or in combination regimens.
• Helps improve progression-free survival in responsive patients.
• Offers a targeted approach to cancer therapy.

Side Effects

• Peripheral neuropathy (numbness, pain, tingling)
• Thrombocytopenia (low platelet count)
• Neutropenia (low white blood cell count)
• Fatigue
• Nausea
• Diarrhea
• Constipation
• Anemia
• Fever
• Vomiting
• Headache
• Rash

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate peripheral neuropathy or other side effects.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if bortezomib is excreted in human milk.
• Liver - Use with caution in patients with moderate to severe liver impairment; dosage adjustments are typically required.
• Kidney - Use with caution in patients with severe kidney impairment; close monitoring is advised, but no specific dose adjustment is usually needed for mild-moderate.
• Lung - Monitor for new or worsening pulmonary symptoms, as interstitial lung disease and pneumonitis have been reported.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.